Allegion enters the week wearing a fresh analyst cut and a stock that has drifted 4% lower over the past month — a combination that keeps the building-products name firmly in the "wait and see" column ahead of its next earnings release in late July.
The Street's patience for Allegion is visibly thinning. Morgan Stanley's Chris Snyder lowered his price target to $142 from $165 this week, maintaining an Equal-Weight rating — a move that landed the day this note was filed and is striking because it echoes a sequence of downward revisions that stretches back across every major house covering the stock. JP Morgan went further in mid-May, cutting both its rating (from Overweight to Neutral) and its target (to $150 from $170), while Barclays and BofA Securities have repeatedly trimmed targets without ever mustering an upgrade. The direction of travel is unambiguous: the consensus mean target has settled near $164, roughly 26% above the current price of $129.85, but with nine Hold-equivalent ratings and just four Buys, the implied upside feels aspirational rather than convictional. Analyst recommendation scores rank in only the 5th percentile of the universe — the Street is as cool on this name as it gets.
Short interest adds a supporting note of caution without turning into an outright alarm. SI has crept up roughly 10.6% over the past month to 4.1% of the float — not a dramatic level, but a steady directional build. The move accelerated post-Q1 earnings: Allegion fell 7.4% the day after its April 28 print and lost nearly 11% over the following five sessions, and short sellers absorbed that dip by rebuilding positions rather than covering. The borrow market remains relaxed — cost to borrow is just 0.47%, and availability is extraordinarily loose at over 2,400% of short interest, meaning there are roughly 24 times as many shares available to lend as are currently borrowed. There is no squeeze dynamic here; the positioning looks methodical rather than crowded.
Options traders lean in a mildly more bullish direction than the analyst desk would suggest. The put/call ratio has eased to 0.27, below its 20-day average of 0.29, with a z-score of -0.8 — not a dramatic reading, but it signals that options flow has been tilted toward calls in recent sessions. The 52-week PCR range runs from 0.07 to 0.65, so the current reading sits in the lower-to-middle portion, consistent with a market that is not actively hedging downside through derivatives despite the price weakness.
The earnings backdrop is the clearest reason for caution. The April print was a genuine setback — a 7.4% single-day drop followed by a 10.9% five-day decline is not a typical "sell the news" reaction. The next event is scheduled for July 24, giving the stock roughly seven weeks to find a catalyst. Factor scores offer little immediate comfort: EPS momentum ranks at the 34th percentile over 30 days and 36th over 90 days, while EPS surprise sits at the 42nd. The one constructive outlier is forward EPS growth, which ranks in the 85th percentile — analysts have revised earnings projections meaningfully higher on a year-over-year basis, a signal that the long-term fundamental case remains intact even as near-term sentiment sours.
Close peers give some context on the broader sector. AOS slid 2.7% on the week and GFF lost 1.7%, suggesting building-products names generally faced selling pressure rather than idiosyncratic weakness in Allegion. SSD and MAS held up better, down less than 1% and roughly flat respectively. Allegion's 1.3% weekly decline was roughly in line with the softer names in the group — it wasn't singled out, but it wasn't a safe haven either.
The July 24 earnings date is the next decisive moment. With the stock still 26% below the average analyst target but carrying a ratchet of downward revisions and a Q1 print that rattled confidence, how management frames guidance for the back half of the year will determine whether the analyst community finally moves to upgrade or continues its slow retreat.
See the live data behind this article on ORTEX.
Open ALLE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
